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Abstract 41 
Background: Hip fracture represents a substantial acute inflammatory trauma, which may constitute 42 
a significant insult to the degenerating brain. Research suggests that an injury of this kind can affect 43 
memory and thinking in the future but it is unclear whether, and how, inflammatory trauma injures 44 
the brain. The impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood 45 
BiomarkErs of brain inflammation and injury in Dementia: a study in acute hip fracture patients 46 
(ASCRIBED) explores this relationship, to understand the effect of inflammation on the progression 47 
of dementia. 48 
Methods: This protocol describes a multi-centre sample collection observational study. The study 49 
utilises the unique opportunity provided by hip fracture operations undertaken via spinal 50 
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anaesthesia to collect cerebrospinal fluid (CSF) and blood, to investigate the impact of acute brain 51 
inflammation caused by hip fracture on the exacerbation of dementia. We will recruit 200 hip 52 
fracture patients with a diagnosis or evidence of dementia; and 200 hip fracture patients without 53 
dementia. We will also recruit ‘Suitable informants’, individuals in regular contact with the patient, 54 
to provide further proxy evidence of a patient’s potential cognitive decline. We will compare these 55 
400 samples with existing CSF and blood samples from a cohort of dementia patients who had not 56 
experienced a systemic inflammatory response due to injury.  This will provide a comparison 57 
between patients with and without dementia who are suffering a systemic inflammatory response; 58 
with stable patients living with dementia.   59 
Discussion: We will test the hypothesis that hip fracture patients living with dementia show elevated 60 
markers of brain inflammation, as well as neuronal injury and Alzheimer-related plaque pathology, in 61 
comparison to (1) stable patients living with dementia and (2) hip fracture patients without 62 
dementia, as measured by biomarkers in CSF and blood. The findings will address the hypothesis 63 
that systemic inflammatory events can exacerbate underlying dementia and inform the search for 64 
new treatments targeting inflammation in dementia. 65 
Trial Registration: ISRCTN43803769. Registered 11 May 2017. 66 
https://doi.org/10.1186/ISRCTN43803769  67 
Keywords: dementia, hip fracture, inflammation, cerebrospinal fluid.  68 
Background 69 
Inflammation is a beneficial physiological response to tissue damage or infection. However, when 70 
inflammation is extensive or not fully resolved, this can damage healthy tissues and disrupt normal 71 
cellular function. Hip fracture represents a substantial systemic inflammatory trauma, common in 72 
older people, which may constitute a significant insult to the degenerating brain and therefore 73 
contribute to the progression or even the onset of dementia. Hip fracture in older people has 74 
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therefore been linked with poor cognitive outcomes, including delirium in the short-term, increased 75 
dependency and cognitive decline, especially in patients with dementia [1, 2, 3].  76 
The association and pathological role of inflammation in dementia has been extensively described 77 
[4]. Studies have shown that microglial cells (the brain’s main macrophage population) are activated 78 
in the vicinity of amyloid plaques in dementia [5]. More recent studies suggest that altered 79 
macrophage function may contribute to dementia [6]. Animal studies have shown that microglial 80 
activation is a consistent feature in dementia and there is evidence that inflammation contributes to 81 
the disease process [7, 8] but the physiological and molecular basis for this remains unclear.  82 
Current evidence from human epidemiological studies, human data from blood, cerebrospinal fluid 83 
and imaging, and animal models, have established that alongside chronic localised inflammation 84 
resulting from and contributing to neurodegenerative diseases such as dementia, there is also 85 
neurodegeneration induced by acute inflammatory processes [9] and changes in amyloid processing 86 
[10]. Understanding this alternative route to neurodegeneration is becoming increasingly important 87 
as the population ages. This is because acute systemic inflammatory episodes, such as infection and 88 
inflammatory trauma, are common in older people with some evidence of this having both acute 89 
[11] and lasting [12] impacts on cognitive function. Therefore, it is plausible that such episodes are 90 
an important cause of decline in people living with dementia, which is clinically almost completely 91 
unaddressed.  92 
With rapid advances in identifying and measuring/testing cerebrospinal fluid (CSF) and blood 93 
biomarkers of brain inflammation, brain injury and Alzheimer-associated amyloid β (Aβ) plaque 94 
pathology, there is the opportunity to study this in humans.  95 
Previous studies in older people with acute systemic inflammation have been limited by small 96 
sample sizes, the lack of adequate control groups and, in particular, have not assessed the impact of 97 
inflammation on recently emerging biomarkers of new brain injury [13].  98 
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One of the other difficulties encountered by research in this area is that hip fracture is an emergency 99 
and studies cannot directly collect pre-fracture data. However, well-validated methods for the 100 
assessment of pre-fracture cognitive ability are available. The Informant Questionnaire for Cognitive 101 
Decline in the Elderly (IQCODE [15] is one example widely-used clinically and for research purposes.  102 
In the United Kingdom (UK) a significant proportion of hip fracture patients undergo surgery within 103 
spinal anaesthesia [16]. This routine clinical procedure involves inserting a needle into the patient’s 104 
spinal space (subarachnoid space) and injecting anaesthetic into the CSF. In this way, CSF can be 105 
collected just before the initiation of anaesthesia, using the same needle that will be used to 106 
administer the anaesthetic agent. This means that older patients undergoing emergency hip fracture 107 
repair surgery are a suitable group in which to measure systemic inflammation, brain inflammation 108 
and CSF markers of brain injury.  109 
The impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood BiomarkErs of 110 
brain inflammation and injury in Dementia: a study in acute hip fracture patients (ASCRIBED) will use 111 
the opportunity provided by hip fracture operations undertaken via spinal anaesthesia to investigate 112 
the impact of acute systematic inflammation upon CSF and blood biomarkers of brain inflammation 113 
and neuronal injury and on the exacerbation of dementia. We will collect samples from patients with 114 
and without dementia who are suffering a systematic inflammatory response (the ASCRIBED cohort). 115 
We will compare ASCRIBED’s ‘unstable’ groups (termed as to refer to the inflammatory response) 116 
with an existing cohort of patients living with dementia who have not experienced a systemic 117 
inflammatory response from an injury (henceforth known as the ‘Oslo’ cohort).  The Oslo cohort will 118 
therefore provide ‘stable’ comparators. The study will shed light on the ability of acute inflammatory 119 
trauma to produce new brain injury in a vulnerable older population. The findings will then inform 120 
the search for new treatments targeting inflammation in dementia. 121 
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Methods 123 
Aims and objectives  124 
In order to have specific measures informing on the severity of prevalent systemic inflammation at 125 
the time of lumbar puncture (i.e., the time of CSF collection), matched to those inflammatory 126 
mediators occurring in the CSF, we will quantify inflammatory mediators (including but not limited 127 
to IL-1β, TNF-α, IL-6) in both peripheral blood and in CSF. In order to assess brain injury we will 128 
measure CSF markers of brain injury (including but not limited to total and phosphorylated tau [T-129 
tau and P-tau, respectively], neurofilament light [NfL] and neurogranin). Brain injury markers will 130 
also be measured in blood. Aβ42/40 ratio in CSF and plasma, measured using immunoassays (Meso 131 
Scale Discovery and Simoa methods, respectively), will be used as a biomarker of cerebral Aβ 132 
pathology. We will also collect an additional 2.5ml of whole blood from patients. Several studies 133 
have recently been published using PAXgene blood collection tubes for later transcriptomic analysis. 134 
Our intention is to place ourselves in the position to examine blood signatures that associate with, 135 
and may be predictive of, particular CSF and clinical outcomes in our patients for later analysis. 136 
Banking these samples will enable further in-depth analysis and is in accordance with the trial ethical 137 
approval and consent process. 138 
 139 
Primary Objective     140 
To determine whether hip fracture patients living with dementia show elevated markers of brain 141 
inflammation in comparison to (1) stable patients living with dementia and (2) hip fracture patients 142 
without dementia, as measured by biomarkers in CSF. CSF inflammation will be measured by TNF-α, 143 
IL-1RA, IL-1β, IL-6 and brain injury and biomarkers will be measured by NfL, neurogranin, T-tau, 144 
synaptotagmin and SNAP-25. 145 
 146 
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Secondary Objectives 147 
To determine whether the magnitude of the brain inflammatory response predicts the quantity of 148 
specific brain injury markers measured in the CSF. Magnitude of the brain injury will be assessed via 149 
brain injury markers T-tau, P-tau, NfL, neurogranin, synaptotagmin and SNAP-25 in CSF. We will also 150 
examine if patients who are Aβ-positive at baseline are more or less likely to have dementia or 151 
develop dementia at follow-up. We will also look for interactions of Aβ positivity with the other 152 
biomarkers in regards to clinical outcome.   153 
Design  154 
This observational study will recruit patients with proximal hip fractures who undergo surgery via 155 
spinal anaesthesia. The majority of patients admitted with a hip fracture are cognitively vulnerable. 156 
This may be a pre-fracture state or an acute reaction to the hip fracture. Clinically, patients arriving 157 
in acute settings do not always arrive with a confirmed dementia diagnosis. However, in the UK, it is 158 
routine clinical practice to cognitively screen hip fracture patients over the age of 60 years. In 159 
England, the Abbreviated Mental Test (AMT) is commonly used [17]. In Scotland, the 4AT is used as 160 
best standard practice [18]. Because evidence highlights that the mapping of a patient’s score on the 161 
4AT on to the AMTS is possible [19, 20], we will use routinely available clinical data to pre-162 
operatively assign recruited patients to one of two groups, either ‘confused’ or ‘non-confused’.  In 163 
this way, we will employ the term confusion to reflect the real-world complexity of the acute 164 
hospital environment and initially assign patients accordingly, based on these existing cognitive 165 
clinical screening practices (see figure 1). Specifically, Group 1 patients will have a pre-op AMT score 166 
of ≤ 8 (England), or a 4AT score of > 1 (Scotland); and Group 2 patients will have a pre-op AMT score 167 
of > 9 (England) or 4AT score of 0 (Scotland).   168 
Whilst these are indicative of the possibility that the patient may have some form of 169 
dementia/cognitive impairment, it is often not possible to obtain confirmative evidence until at least 170 
1-month post-op. Using the AMT or 4AT scores allows us to allocate patients to a group at the 171 
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recruitment stage. However, we will also take into account any subsequent evidence of dementia in 172 
the analysis, by gaining permission/consent to access a patient’s notes and/or where possible, a 173 
consented suitable informant (someone who has contact with the patient at least once a month 174 
face-to-face or via telephone) via the Informant Questionnaire for Cognitive Decline in the Elderly 175 
(IQCODE). This will inform what final group cohort the patient is then allocated to. In the absence of 176 
a formal documented diagnosis of dementia and in accordance with previous research [21, 22], 177 
patients with an associated suitable informant IQCODE score of 3.31 and above will be assessed as 178 
having sufficient evidence of dementia to be allocated to the corresponding group cohort.  179 
INSERT FIGURE 1: STUDY DIAGRAM AND GROUP ALLOCATION OF PATIENTS  180 
Setting  181 
The study setting is acute trauma wards in hospitals across England and Scotland to which 182 
individuals suffering Neck of Femur (NoF) fractures are admitted. In all instances, the investigator(s) 183 
will be able to demonstrate a potential for recruiting the required number of suitable participants 184 
within the agreed recruitment period (i.e. the investigator(s) regularly treat(s) the target 185 
population). For these reasons, the study management team will target NHS Hospitals with large 186 
annual admission rates of NOF fractures with sufficiently high percentages of operations being 187 
undertaken via spinal anaesthesia. This information was readily available through the National Hip 188 
Fracture Database (NHFD) for all NHS Trusts in England [17]. In Scotland, we targeted large centres 189 
known to the study group and with existing expertise in collecting CSF for research purposes.  190 
Participants  191 
We will be collecting samples and data from two groups of patient participants (n=200 in each 192 
group). Due to the cognitively vulnerable nature of the patient population and feasibility learning in 193 
relation to dementia diagnosis rates of our target population [23], we will seek proxy information 194 
about pre-fracture cognition to inform grouping allocation for analysis. Consequently, we will also 195 
seek  written consent from “suitable informants” as defined by the inclusion criteria below, to 196 
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complete the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE). The 197 
recruitment of a suitable informant for each patient is desirable, but not essential. The eligibility 198 
criteria for patient participants and suitable informant participants are as follows: 199 
Patient inclusion criteria: 200 
Group 1: ‘Confused’ hip fracture patients 201 
Inclusion Criteria: 202 
1) Patient must have had a confirmed proximal hip fracture requiring an operation and be aged 203 
60 or older at the time of operation; 204 
2) Patient has a pre-operative Abbreviated Mental Test Score (AMTS) of 8 or below; or 4AT 205 
score of 1 or above;  206 
3) Patient must be undergoing spinal anaesthesia. 207 
Exclusion criteria: 208 
1) Decision taken not to have hip surgery; 209 
2) Patient has head trauma with bleeding as indicated by a CT scan; 210 
3) Patient has confirmed diagnosis of Parkinson’s disease; 211 
4) Patient not expected to survive beyond 4 weeks; 212 
5) Patient’s fall and subsequent hip fracture caused by acute Stroke, indicated by CT and/or 213 
MRI scan and/or clinical examination; 214 
6) Patient already enrolled in a Clinical Trial of an Investigational Medicinal Product (CTIMP). 215 
Group 2: ‘Non-confused’ hip fracture patients 216 
Inclusion Criteria: 217 
1) Patient must have had a confirmed proximal hip fracture requiring an operation and be aged 218 
60 or older at the time of operation;  219 
2) Patient has a pre-operative AMTS of 9 or above; or 4AT score of 0;  220 
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3) Patient must be undergoing spinal anaesthesia. 221 
Exclusion criteria: 222 
1) Decision taken not to have hip surgery; 223 
2) Patient has head trauma with bleeding as indicated by a CT scan.  224 
3) Patient has confirmed diagnosis of Parkinson’s disease;  225 
4) Patient not expected to survive beyond 4 weeks;  226 
5) Patient’s fall and subsequent hip fracture caused by acute Stroke, indicated by CT and/or 227 
MRI scan and/or clinical examination; 228 
6) Patient already enrolled in a Clinical Trial of an Investigational Medicinal Product (CTIMP). 229 
Suitable informants 230 
Inclusion Criteria: 231 
1) Individual has a minimum of once a month face-to-face or telephone contact with the 232 
patient; 233 
2) Individual is able and consents to complete the IQCODE. 234 
Exclusion Criteria:  235 
1) Individual under 16 years of age. 236 
 237 
Recruitment and Consent Procedures  238 
A three-phase recruitment process has been guided by conversations with clinical and academic 239 
collaborators and previous experience recruiting from this patient group [23]. 240 
1) Research Nurses will collaborate with relevant clinical staff (including but not exclusively the 241 
study ward Trauma Co-ordinators and key Emergency Department colleagues) to identify all new hip 242 
fracture admissions and screen for pre-recruitment eligibility; 243 
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2) Each patient (and where possible their potential suitable informant) will be approached by a 244 
Research Nurse who will provide information about the study as soon as clinically appropriate. 245 
During this initial approach, the Research Nurse will also assess the mental capacity of the patient; 246 
3) The Research Nurse will approach the patient (where possible) and the identified suitable 247 
informant to obtain full written informed consent. In cases where written consent is not possible, 248 
ethical approval allows for witnessed verbal consent. 249 
In English trial sites, in line with Principle 1 of the Mental Capacity Act 2005 [24], a potential patient 250 
participant will be assumed to have capacity until it is established otherwise. When this is the case 251 
and all practical steps to help them to engage in the decision making process have been tried 252 
(Principle 2 of Mental Capacity Act 2005), the site trial team will seek a personal consultee. This 253 
person will be someone who is engaged in care for the participant (not professionally or for 254 
payment) or is interested in his/her welfare and is prepared to be consulted. This may be a family 255 
member, carer or close friend, or attorney acting under Lasting Power of Attorney. This person can 256 
also act as a suitable informant if they fulfil the inclusion criteria. 257 
If a potential personal consultee is not available or declines to take part, alternatively a nominated 258 
consultee will be sought. This will be a person independent of the research study and who is willing 259 
to be consulted about the participation of a person who lacks capacity where reasonable steps have 260 
been taken to identify a personal consultee. This may be someone who knows the patient in a 261 
professional capacity e.g. social worker, ward staff member, paid carer or GP, provided they have no 262 
connection to the research study. 263 
In Scottish sites, in line with the Adults with Incapacity Act 2000 [25], where a potential patient 264 
participant is assessed not to have capacity, a welfare guardian, welfare attorney or nearest relative 265 
will be sought and asked to consent in relation to participation in research (this person will be 266 
henceforth known as a legal representative). This procedure will be undertaken once an assessment 267 
of capacity has been made in relation to the specific decision regarding the research participation, 268 
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any barriers to participating in the consent process have been removed and the local research 269 
worker feels the individual cannot retain information long enough to use it in order to arrive at a 270 
decision. 271 
Legal representatives may be involved in conversations regarding the consenting process. However, 272 
they will be asked to differentiate between expressions of their own views and reporting the known 273 
values and/or views of the potential patient participant. If the potential participant is unable to 274 
consent for himself or herself, then consent will be sought on their behalf from a suitable legal 275 
representative. 276 
In cases where gaining full written consent is not possible research workers may take witnessed 277 
verbal consent (patients or legal representatives) or agreement (personal consultees). For patients 278 
this may be needed due to an inability to write because of injury. With personal consultees or legal 279 
representatives this may be due to distance therefore study information may be conveyed over the 280 
phone with relevant forms sent via email if appropriate. Where witnessed verbal 281 
agreement/consent is taken, full written agreement/consent will be sought where practically 282 
possible. A record of all witnessed verbal consent will be added to the patient’s notes. 283 
In both England and Scotland, if during a follow-up assessment the patient is assessed by a local 284 
research worker to have regained capacity (a possibility in the case of some cognitive impairments 285 
such as delirium); he/she will be approached about continuing to participate in the study and asked 286 
to give informed consent. Should they choose to withdraw from the study at this point, the study 287 
team reserve the right to retain any data and samples collected up until the point of the patient’s 288 
withdrawal. This will be clearly stated in the patient and Consultee (English sites)/Legal 289 
Representative (Scottish Sites) Information Sheets.  290 
This three-phase process will be closely monitored to identify trends that might be leading to over or 291 
under recruitment from specific groups. For example, if sites are consenting purely via personal 292 
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consultees (England) or legal representatives (Scotland), monitoring will enable corrective actions 293 
and provide information to mitigate these recruitment trends.  294 
 295 
Recruiting patients with fluctuating and/or reduced capacity in England and Scotland 296 
The aims of this study are incompatible with only enrolling patients with minimal or mild confusion. 297 
It is important to ensure findings are broadly applicable to those patients with a pre-existing 298 
diagnosis or evidence of dementia. Participants who lack capacity to give informed consent must 299 
therefore be included. In this situation, the patient’s agreement to participate will still be obtained 300 
to their best level of understanding (in line with legislative frameworks in England [24] and Scotland 301 
[25]). Where patients in England are assessed as lacking capacity to make a decision regarding their 302 
initial or continued involvement with the study, we will seek a personal or nominated consultee 303 
agreements [26]. In Scottish study sites where a patient is assessed not to have capacity, a legal 304 
representative will be sought and asked to consent in relation to the patient’s participation in the 305 
research [27]. 306 
 307 
Approaching patients post-operatively  308 
Where possible, the patient will be approached at a clinically suitable time approximately 48 hours 309 
(± 4 hours) following their operation. However, in order to facilitate patient recruitment and because 310 
successful collection of a sufficient number of pre-operative CSF samples is the priority for this study, 311 
sites are encouraged to screen and recruit patients from Monday-Friday. This is on the 312 
understanding that should a patient be consented on a Thursday/Friday, it may not be possible to 313 
complete the 48-hour follow-up due to insufficient Research Nurse cover during weekends.  314 
During the 48-hour follow-up point, we will aim to collect the post-operative blood sample and Mini-315 
Mental State Examination - 2nd Edition, Short-Form version (MMSE~2: SV) data. As appropriate, the 316 
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research nurse will remind the patient of the study, reassess capacity (as required) and complete 317 
pre-consented study related procedures. In English sites, for patients who previously provided 318 
informed consent on their own behalf but are as assessed as having since lost capacity at this follow-319 
up point, we will seek a personal or nominated consultee agreements [24]. As part of the patient 320 
consent form for Trusts based in England, patients will be asked to provide contact details for 321 
someone who may be willing to act as a personal consultee in the event that the patient loses 322 
capacity. Patients will also be asked to sign an advanced statement of intent, stating that should they 323 
be assessed as having lost capacity post-operatively, they would still like to be involved in the study 324 
should a consultee be available. A more detailed overview of the recruitment process is shown in 325 
Figure 2: Recruitment overview. 326 
INSERT FIGURE 2: RECRUITMENT OVERVIEW AND PARTICIPANT FLOW 327 
Data Collection  328 
Day of Operation  329 
The research nurse and/or anaesthetist at the time of the hip fracture operation will be responsible 330 
for collecting 18.5ml of whole blood (1 x 6.0ml of blood ethylenediaminetetraacetic acid (EDTA) 331 
tube, 2 x 5.0ml serum tube and 1 x 2.5ml PAXgene tube) and the collection of 2.0 – 6.0 ml of CSF 332 
(anaesthetist only).  333 
Sites will be instructed to centrifuge CSF samples within one hour of sample collection at 2000G for 334 
10 minutes. If CSF samples are not centrifuged within a maximum of 2 hours of collection, site teams 335 
will be informed to destroy the samples and alert the study management team accordingly. Blood 336 
serum samples will be centrifuged at 2000G for 15 minutes, within one hour of collection. If any 337 
blood serum samples are not centrifuged within 3 hours of collection, they must be rejected and 338 
destroyed; and the study management team notified accordingly. The EDTA and PAXgene samples 339 
will not require centrifugation and sites are instructed to leave these to rest at room temperature 340 
for 2 hours, following inversion.  341 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
ASCRIBED Protocol Paper 
__________________________________________________________________________________ 
15 
 
Once processed and ready for storage, the CSF, EDTA and blood serum samples will be aliquotted 342 
into 0.5ml samples within 1.5ml capacity Cryotubes, and stored in a specific patient Cryobox. Both 343 
the Cryobox and all of the individual Cryotubes used for patient sample storage are labelled with the 344 
patient’s unique study identifier number and colour coded to match the sample type being stored. 345 
PAXgene samples are also labelled accordingly but remain stored in their initial vacutainers, inside 346 
the corresponding patient’s Cryobox. The Cryobox will then be stored in a -80֯ Celsius freezer at the 347 
local research site. All of the sample collection, processing and storage times for each patient will be 348 
recorded within the study’s electronic database for monitoring purposes.  349 
Once a site has successfully recruited and collected samples for 10 patients, the study management 350 
team will arrange for a courier to collect and deposit the samples at the Norwich Biorepository for 351 
long-term storage, until the final sample analysis is ready to be started. All sample transfers will be 352 
completed on a same day delivery basis, using dry ice to maintain sample cooling. Once at the 353 
Norwich Biorepository, samples will be monitored against the electronic database records and 354 
sample transfer log, for completeness and accuracy. Samples will then be deposited in a -80֯ Celsius 355 
freezer within the Norwich Biorepository. Any discrepancies will be followed up with the local 356 
research team and recorded in the electronic database accordingly.  357 
Spinal anaesthesia will be performed according to local trust procedures. After placement of the 358 
needle to deliver the spinal anaesthetic, and prior to administration of the anaesthetic agent, a 359 
sample of between 2 – 6ml of CSF will be collected. Patients unable to provide a sufficient CSF 360 
sample will be withdrawn from the study and any prior samples collected destroyed according to 361 
Local Trust Policy.  362 
During collection of the CSF, the patient will be monitored. Should the patient’s discomfort become 363 
too great, the anaesthetist will stop collecting the CSF. Headaches (‘post-dural-puncture headache’ 364 
or ‘PDPH’) are a common side effect of spinal anaesthesia and typically occur within two to three 365 
days following the procedure. After taking advice from anaesthetists, it was identified that the risk of 366 
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patients experiencing a PDPH may be slightly higher for patients taking part in this study because of 367 
the additional CSF withdrawn. The incidence of PDPH’s will therefore be monitored as part of 368 
routine care using standard local procedures. Any PDPH observed by the clinical team will be 369 
assessed for severity and reported as an adverse event. The incidence rates of PDPH’s will be 370 
monitored and review by the Data Monitoring and Ethics Committee (DMEC) and Study Steering 371 
Committee (SSC). However, the risk is expected to be negligible.   372 
Post-op 48 hours (± 4 hours) 373 
2 x 5.0ml blood (serum tube) will be collected from the patient. Every effort will be made to collect 374 
post-operative bloods within this time window, but this may not always be possible. Therefore, 375 
research nurses will collect the MMSE~2: SV data and bloods at the next earliest opportunity but not 376 
beyond 60 hours post-op. The time point at which these samples and data are collected will be 377 
noted and fed into the analysis. Sites consistently collecting samples outside the 48 (± 4 hours) 378 
window will be reviewed by the Study Management Group (SMG) who will decide if they should be 379 
withdrawn. For patients recruited on a Thursday or Friday, it is accepted that this follow-up may not 380 
be possible due to insufficient Research Nurses across weekends.  381 
Post-op 1-month (± 5 days) 382 
The 1-month post-op period will provide clinical teams with an opportunity to contact the patient’s 383 
General Practitioner (GP) and review their case notes to assess if the patient has a pre-existing 384 
documented diagnosis of dementia, as well as record some additional clinical measures and test 385 
results. If the patient has an eligible suitable informant, clinical teams will also use this time to 386 
complete IQCODE assessment if they have not already done so.  387 
INSERT TABLE 1: SAMPLE AND DATA COLLECTION SCHEDULE 388 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
ASCRIBED Protocol Paper 
__________________________________________________________________________________ 
17 
 
Sample Size 389 
We will recruit 200 patients with dementia and hip fracture; and 200 patients without dementia but 390 
who have experienced a hip fracture. This sample size is pragmatically based upon what would 391 
appear to be achievable in the time available and with consideration of likely statistical power. 392 
Without adjustment, a sample size of 200 subjects per group will provide statistical power of 90% to 393 
detect a mean between group mean differences of 0.33 standard deviations in any outcome variable 394 
using a two-sided significance level of 5%. Assuming confounding variables entered into a General 395 
Linear Model ‘explain’ no more than 25% of the total variation (i.e. the co-efficient of determination, 396 
R2, is less than 0.25), then this sample size should provide 90%. Power to detect an ‘adjusted’ mean 397 
difference of around 0.37 residual standard deviations [28]. In either case, this would be deemed a 398 
relatively small effect to be detected with high probability.   399 
Data will be collected initially from two different groups:   400 
Group 1: Pre-operative acute hip fracture patients with confusion; 401 
Group 2: Pre-operative acute hip fracture patients without confusion. 402 
In respect of Group 1 (those with confusion), the AMT (England) and 4AT (Scotland) score indicate 403 
that a patient may be living with dementia. However, this may not be confirmed until 1-month post-404 
op when reviewing the patient’s case notes, contacting their GP or reviewing their relevant Suitable 405 
Informant’s IQCODE Scores. Based on prior research, we anticipate that up to 50% of patients who 406 
have an AMT score of 8 or less (England) or 4AT score of 1 or above (Scotland) will have dementia 407 
(diagnosed or undiagnosed/vectored) [23]. Therefore, up to 400 may need to be recruited to this 408 
group. Recruitment will be monitored and stopped for Group 1 as soon as we receive 200 patients 409 
with confirmed dementia required for the study.  410 
We will also collect data from patients without confusion (Group 2), who are unlikely to be 411 
confirmed with dementia at 1-month post-op. These patients will be included in the non-dementia 412 
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group. Again, recruitment will be monitored and stopped from this group once 200 non-dementia 413 
patients have been included. The number required from this group will be dependent upon the non-414 
dementia confirmation rate for this group. 415 
There will be a number of patients from Group 1 (Pre-operative acute hip fracture patients with 416 
confusion) for whom we cannot find evidence of dementia at 1-month post-op. The samples and 417 
data from this (confused, non-dementia) group will be deposited into a biobank at the Norwich 418 
Biorepository, for use in future research studies. In cases where patients were initially in Group 2 419 
(Pre-operative acute hip fracture patients without confusion) but where evidence of dementia is 420 
available at 1 month post-op, we will reallocate these patients to the dementia patient group. 421 
Comparable data will also be provided from a third group (Oslo Cohort) of 200 ‘stable’ patients living 422 
with a confirmed dementia diagnosis, taken from existing memory clinic data (Norwegian Registry of 423 
Persons with Cognitive Symptoms (NorCog) (Reference: S-08143a and 2017/371). Samples for this 424 
group are already available, as lumbar puncture is part of the diagnostic workup of patients included 425 
in the Norcog registry (Reference: S-08143a). These samples were analysed in 2017 at Sahlgrenska 426 
for the following: Aβ38, Aβ40, Aβ42, 10xAb42/Ab40, YKL-40, IL-1β, IL-6, IL-8, TNF-α, G36-NG2. The 427 
respective regional committee responsible have already provided permission to compare these 428 
results with those gathered in the present study.  429 
 Thus, we shall assemble data from 3 groups (hip fracture and dementia, hip fracture and non-430 
dementia, stable and dementia), each with an expected 200 subjects. Please (see Figure 1: Study 431 
diagram and group allocation of patients). 432 
Analysis  433 
All analyses will be conducted according to a detailed Statistical Analysis Plan (SAP), agreed by the 434 
Study Management Group (SMG) prior to analysis. A summary of the main analyses are given below 435 
however: 436 
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Primary hypothesis: We will address the primary hypothesis, that systemic inflammation arising 437 
from hip fracture leads to an acute brain injury, by comparing the level of inflammatory and 438 
neuronal injury CSF and blood markers between the three groups defined above. Accordingly, we 439 
predict raised inflammatory and injury markers for the confirmed dementia-hip fracture group 440 
compared to the medically stable dementia group (Oslo cohort) and compared to the non-dementia 441 
hip fracture group.  442 
Each of the markers will be compared across groups using a general linear model with the marker as 443 
the dependent variable (i.e. a separate model for each biomarker). The initial model will simply 444 
include group as an explanatory factor. A further model will then be constructed, including potential 445 
confounding variables, such as age, to provide an adjusted between group mean difference 446 
(comparing fracture patients with dementia to fracture patients without and fracture patients with 447 
dementia to stable dementia patients), together with 95% confidence intervals and significance test. 448 
In the event of the residuals for these models not appearing normally distributed, an appropriate 449 
transformation will be applied, such as a logarithmic transformation. We also predict that patients 450 
with dementia will have significantly worse cognitive and functional informant-based scores. A 451 
similar analysis will be conducted with cognitive and functional scores as the dependent variable. 452 
Secondary hypothesis: The secondary hypothesis is that the magnitude of the brain inflammatory 453 
response will predict the quantity of specific brain injury markers (phospho-tau, NfL, neurogranin, 454 
synaptotagmin, SNAP-25) measured in the CSF. The strength of inter-relationship between the 455 
inflammatory and injury markers outlined will be examined using correlation coefficients. These will 456 
also be adjusted for potential confounding factors using partial correlation coefficients. 457 
Analysis of the samples will take place at UEA, Trinity College Dublin and the University of 458 
Gothenburg. Should additional information become available during the course of the study, we will 459 
ensure that we use the most appropriate analysis available to answer the research questions. 460 
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• CSF will be analysed for a number of inflammatory and neuronal injury markers. These 461 
include, but are not limited to: TNF-α, IL-1RA, IL-1β, IL-6, sTREM2, YKL-40, T-tau, P-tau, Aβ38, Aβ40, 462 
Aβ42, neurogranin, synaptotagmin and SNAP-25; 463 
• Blood collected pre-operatively and at 48 hours (± 4 hours) will be analysed for TNF-α, IL 464 
1RA, IL-1β, IL-6, T-tau and NfL; 465 
• Blood collected pre-operatively will also be genotyped for the APOE ε2/ε3/ε4 polymorphism 466 
at UEA;  467 
• PAXgene blood for later transcriptomic analysis looking for blood signatures that associate 468 
with, and may be predictive of, particular CSF and clinical outcomes in our patients. 469 
Discussion  470 
Despite significant investment, disease-modifying treatments for dementia are still absent and there 471 
has been no significant treatment breakthrough for 15-20 years [29]. Inflammation is a vital part of 472 
the immune system's response to injury and infection which may become harmful if exaggerated or 473 
unresolved. There is now growing evidence that harmful inflammation in the brain is aetiological and 474 
contributed to the pathophysiology of dementia [30]. 475 
Recent research highlights acute illnesses or injuries that cause inflammation throughout the body, 476 
such as infection, trauma and surgery, can accelerate the speed of decline in dementia [31, 32]. For 477 
example, an infection in a hospitalised older person with dementia is linked to a higher long-term 478 
worsening of that person’s symptoms. The underlying mechanisms linking inflammation, cognition 479 
and dementia progression remain greatly under-researched, with almost no studies in humans. This 480 
lack of research impacts on the search for new treatments targeting inflammation in dementia.  481 
Thus this study will develop understandings of the role of inflammatory response in dementia and 482 
support developing pharmaceutical interventions. Additionally it will inform ways to predict 483 
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deterioration in dementia. Exploration of new potential disease pathways remains essential for 484 
finding new therapeutic targets.  485 
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cerebrospinal fluid (CSF), Data Monitoring and Ethics Committee (DMEC), 530 
ethylenediaminetetraacetic acid (EDTA), General Practitioner (GP), Informant Questionnaire for 531 
Cognitive Decline in the Elderly (IQCODE), Mini-Mental State Examination - 2nd Edition, Short-Form 532 
version (MMSE~2: SV), National Health Service (NHS), National Hip Fracture Database (NHFD), neck 533 
of femur (NOF), post-dural puncture headache (PDPH), Study Management Group (SMG), Study 534 
Steering Committee (SSC), United Kingdom (UK), Statistical Analysis Plan (SAP).  535 
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Figure Titles/Legends  641 
Figure 1: Study Diagram and Group Allocation of Patients 642 
Figure 2: Recruitment Overview and Participant Flow 643 
Table 1: Sample and Data Collection Schedule 644 
1 Taken if patient’s capacity status has changed from pre-operative time period (Eng. only); 645 
1 Should the time window be unworkable, research nurses will collect MMSE~2: SV data and bloods at the 646 
next earliest opportunity but not beyond 60 hours post-op; 647 
1 Can be gained at any point before the 1-month (± 5 days) time period elapses. 648 
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Table 1: Sample and Data Collection Schedule 
 
 
Admission/Pre-Op 
Period 
Day of 
Operation 
Post-Op Period 
TIMEPOINT  
 Day  
0 
48 (± 4 
hours) 
post-op  
Time 1  
(1 month ± 5 
days) 
Consent/ 
Agreement 
X  X1 
 
AMT and/or 4AT X  X2 
 
Collection of blood EDTA 
sample  
(6 ml) 
 
 
 
X 
  
Collection of blood serum 
clotted sample  
(10 ml) 
  
X 
 
X2 
 
Collection of Cerebrospinal 
fluid (CSF) sample                              
(≥ 2.0ml) 
 
 
 
X 
  
MMSE~2: SV 
 
 
 X2  
IQCODE                                
(To be completed by the 
suitable informant) 
 
 
  
X3 
 
Evidence of dementia from 
patient’s medical/GP 
records 
    
X3 
Medication information    X3 
Collection of blood 
PAXgene RNA sample 
(2.5ml) 
  
X 
  
 
                                                          
1 Taken if patient’s capacity status has changed from pre-operative time period (Eng. only); 
2 Should the time window be unworkable, research nurses will collect MMSE~2: SV data and bloods at the 
next earliest opportunity but not beyond 60 hours post-op; 
3 Can be gained at any point before the 1-month (± 5 days) time period elapses. 
 
Table 1 Click here to access/download;Table;table 1 ASCRIBED.docx
Figure 1: Study diagram and allocation of patients  
 
 
 
 
 
 
 
 
 
 
 
Pre-operative acute hip 
fracture patients                    
with confusion                             
(AMTS ≤ 8; 4AT ≥ 1) 
Pre-operative acute hip 
fracture patients                 
without confusion                             
(AMTS > 8; 4AT = 0) 
Confirmed diagnosis or 
evidence of Dementia at 
1-month post-op? 
Confirmed diagnosis or 
evidence of Dementia at 
1-month post-op? 
GROUP 1                                           
Non-Stable (hip fracture) 
patients with confirmed 
dementia                                                                             
(n = 200) 
GROUP 2                                           
Non-Stable (hip fracture) 
patients without 
confirmed dementia                                                       
(n = 200) 
Norwich Biorepository                  
Samples stored at the 
Norwich Biorepository for 
future research purposes 
OSLO COHORT                  
Stable (non-hip fracture) 
patients with confirmed 
dementia                               
(n = 200)                                         
Previously collected 
“Non-hip fracture”                   
(i.e. stable) patients                
with confirmed dementia  
NO YES 
YES NO 
Figure 1 Click here to access/download;Figure;ASCRIBED_Figure
1.docx
Figure 2: Recruitment overview and participant flow  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient eligible for trial? ASCRIBED 
End Point 
Patient has capacity to consent? 
Professional Consultee 
available? 
England Scotland 
Legal Representative 
available? 
Personal Consultee 
available? 
NO 
YES 
NO YES 
NO 
ASCRIBED 
End Point 
YES 
Patient admitted to trial site 
NO 
NO 
Consent obtained? 
YES ASCRIBED 
End Point 
NO 
YES 
Pre-Operative:                                                   
CSF and Blood samples taken 
Post-Operative:                                                                                                           
Reassess capacity and proceed to collect written consent, consultee 
agreement (Eng) or legal representative consent (Scot) (if pre-operative 
capacity status has altered).  
Consent/agreement to continue? 
 
NO 
ASCRIBED 
End Point 
1-month (± 5 days) Post-Operation:                                                        
Check Hospital and GP Notes to see whether diagnosis of dementia 
recorded. Check outcome of IQCODE. 
Post-Operation (48 hours ± 4 hours):                                                                                   
- Collect blood sample                                                                                                     
- MMSE~2: SV 
ASCRIBED 
End Point 
*If an eligible suitable informant is available: Consent Taken and IQCODE completed – This can be 
completed anytime from consent/consultee advice being taken up to 1-month post-operatively. 
≥ 2.0ml of CSF collected? ASCRIBED 
End Point 
NO 
YES 
Figure 2 Click here to access/download;Figure;ASCRIBED_Figure
2.docx
